Corneal intrastromal MyoRing implantation in keratoconus treatment

Abstract

Purpose The aim of this study was to evaluate the efficacy and safety of MyoRing implantation into a corneal stromal pocket using the corneal intrastromal implantation system for keratoconus (KC) treatment. Patients and methods This nonrandomized prospective clinical trial included 22 eyes of 22 KC patients. The MyoRing was inserted into a 300-μm corneal pocket centered on the corneal reflex. Follow-up for 6 months with measurement of uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA), and Pentacam corneal imaging was performed. Any surgical complication was reported. Results There was a high statistically significant improvement in UCVA, BCVA, K 1 , K 2 , and K m when comparing preoperative with all postoperative values ( P P K 1 , K 2 , and K m values decreased from 48.45 ± 3.79, 54.46 ± 3.94, and 51.31 ± 3.56 to 45.79 ± 2.97, 42.56 ± 3.17, and 49.07 ± 3.33, respectively, at 6 months postoperatively. Meanwhile, no statistically significant changes in the mean corneal astigmatism and thinnest location values were reported ( P > 0.05). Three patients with severe KC underwent position adjustment of the implant. No detectable intraoperative or postoperative complications were observed in any of the cases. Conclusion MyoRing intrastromal implantation could represent an efficient, safe, modifiable, and simple therapeutic option for KC management.